What top creators are saying about Viatris Inc.(VTRS)

A global pharmaceutical company that won a patent dispute for a generic version of semaglutide.

2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.

Creator sentiment — last 30 days

Based on 1 scored insight about Viatris Inc..

Strongly bearish
avg -0.70
0 bullish0 neutral1 bearish

Top creators covering Viatris Inc. (VTRS)

The 2 sources with the most insights about Viatris Inc. on Kazuha.

Latest insights about Viatris Inc. (VTRS)

AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.

Yesterday

Very Bearish
Target: N/A

A shift in clinical practice toward tapering patients off 'cocktails' of multiple drugs could lead to a long-term decline in the total addressable market for legacy psychiatric medications.

Friday, July 25, 2025

Very Bullish

Won a significant patent feud against Novo Nordisk regarding semaglutide, a major step toward a generic version of Wegovy, which is seen as hugely positive news not yet priced into the stock.

Discussed alongside Viatris Inc. (VTRS)

Other assets that creators frequently mention in the same content as Viatris Inc..

Frequently asked

Which podcasters and creators cover Viatris Inc. (VTRS) the most?

The most active sources covering Viatris Inc. (VTRS) on Kazuha are The New York Times, @BeatTheDenominator. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.

How many insights about Viatris Inc. (VTRS) are on Kazuha?

Kazuha has indexed 2 AI-extracted insights about Viatris Inc. (VTRS) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.

What other assets do creators discuss alongside Viatris Inc. (VTRS)?

Creators covering Viatris Inc. (VTRS) most frequently also discuss LLY, PFE, NVO, TAK, HIMS. See the "Discussed alongside" section above for full asset pages.